Targeting Cdc20 As a Novel Cancer Therapeutic Strategy.

Lixia Wang,Jinfang Zhang,Lixin Wan,Xiuxia Zhou,Zhiwei Wang,Wenyi Wei
DOI: https://doi.org/10.1016/j.pharmthera.2015.04.002
IF: 13.4
2015-01-01
Pharmacology & Therapeutics
Abstract:The Anaphase Promoting Complex (APC, also called APC/C) regulates cell cycle progression by forming two closely related, but functionally distinct E3 ubiquitin ligase sub-complexes, APC(cdc20) and APC(cdh1), respectively. Emerging evidence has begun to reveal that Cdc20 and Cdh1 have opposing functions in tumorigenesis. Specifically, Cdh1 functions largely as a tumor suppressor, whereas Cdc20 exhibits an oncogenic function, suggesting that Cdc20 could be a promising therapeutic target for combating human cancer. However, the exact underlying molecular mechanisms accounting for their differences in tumorigenesis remain largely unknown. Therefore, in this review, we summarize the downstream substrates of Cdc20 and the critical functions of Cdc20 in cell cycle progression, apoptosis, ciliary disassembly and brain development. Moreover, we briefly describe the upstream regulators of Cdc20 and the oncogenic role of Cdc20 in a variety of human malignancies. Furthermore, we summarize multiple pharmacological Cdc20 inhibitors including TAME and Apcin, and their potential clinical benefits. Taken together, development of specific Cdc20 inhibitors could be a novel strategy for the treatment of human cancers with elevated Cdc20 expression. (C) 2015 Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?